Greg M. Delgoffe

Greg M. Delgoffe

Auto-generated profile, based on publicly available information

Greg M. Delgoffe

Department of Immunology, University of Pittsburgh, Pittsburgh, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2021 in Nature
Verified
Journal Article
Closed access
PDF file
MWMcLane J. Watson
McLane J. Watson
PVPaolo D. A. Vignali
Paolo D. A. Vignali
SMSteven J. Mullett
Steven J. Mullett
AOAbigail E. Overacre-Delgoffe
Abigail E. Overacre-Delgoffe
RPRonal M. Peralta
Ronal M. Peralta
GDGreg M. Delgoffe
Greg M. Delgoffe

4 January 2021 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
NSNicole Scharping
Nicole Scharping
DRDayana B. Rivadeneira
Dayana B. Rivadeneira
AMAshley V. Menk
Ashley V. Menk
PVPaolo D. A. Vignali
Paolo D. A. Vignali
BFB. Rhodes Ford
B. Rhodes Ford
GDGreg M. Delgoffe
Greg M. Delgoffe

1 August 2016 in Immunity
Verified
Journal Article
Closed access
NSNicole Scharping
Nicole Scharping
AMAshley V. Menk
Ashley V. Menk
RMRebecca S. Moreci
Rebecca S. Moreci
RWRyan D. Whetstone
Ryan D. Whetstone
RDRebekah E. Dadey
Rebekah E. Dadey
GDGreg M. Delgoffe
Greg M. Delgoffe

29 April 2021 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
KDKristin DePeaux
Kristin DePeaux
GDGreg M. Delgoffe
Greg M. Delgoffe

1 January 2017 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
NSNicole Scharping
Nicole Scharping
AMAshley V. Menk
Ashley V. Menk
RWRyan D. Whetstone
Ryan D. Whetstone
XZXue Zeng
Xue Zeng
GDGreg M. Delgoffe
Greg M. Delgoffe
Blockade of the coinhibitory checkpoint molecule PD-1 has emerged as an effective treatment for many cancers, resulting in remarkable responses. However, despite successes in the clinic, most patients do not respond to PD-1 blockade. Metabolic dysregulation is a common phenotype in cancer, but both patients and tumors are metabolically heterogeneous. We hypothesized that the deregulated oxidative energetics of tumor cells present a metabolic barrier to antitumor immunity through the generation of a hypoxic microenvironment and that normalization of tumor hypoxia might improve response to immunotherapy. We show that the murine tumor lines B16 and MC38 differed in their ability to consume oxygen and produce hypoxic environments, which correlated with their sensitivity to checkpoint blockade. Metformin, a broadly prescribed type II diabetes treatment, inhibited oxygen consumption in tumor cells in vitro and in vivo, resulting in reduced intratumoral hypoxia. Although metformin monotherapy had little therapeutic benefit in highly aggressive tumors, combination of metformin with PD-1 blockade resulted in improved intratumoral T-cell function and tumor clearance. Our data suggest tumor hypoxia acts as a barrier to immunotherapy and that remodeling the hypoxic tumor microenvironment has potential to convert patients resistant to immunotherapy into those that receive clinical benefit. Cancer Immunol Res; 5(1); 9–16. ©2016 AACR.

1 February 2018 in Cell Reports
Verified
Journal Article
Open access
AMAshley V. Menk
Ashley V. Menk
NSNicole Scharping
Nicole Scharping
RMRebecca S. Moreci
Rebecca S. Moreci
XZXue Zeng
Xue Zeng
CGCliff Guy
Cliff Guy
GDGreg M. Delgoffe
Greg M. Delgoffe
To fulfill bioenergetic demands of activation, T cells perform aerobic glycolysis, a process common to highly proliferative cells in which glucose is fermented into lactate rather than oxidized in mitochondria. However, the signaling events that initiate aerobic glycolysis in T cells remain unclear. We show T cell activation rapidly induces glycolysis independent of transcription, translation, CD28, and Akt and not involving increased glucose uptake or activity of glycolytic enzymes. Rather, TCR signaling promotes activation of pyruvate dehydrogenase kinase 1 (PDHK1), inhibiting mitochondrial import of pyruvate and facilitating breakdown into lactate. Inhibition of PDHK1 reveals this switch is required acutely for cytokine synthesis but dispensable for cytotoxicity. Functionally, cytokine synthesis is modulated via lactate dehydrogenase, which represses cytokine mRNA translation when aerobic glycolysis is disengaged. Our data provide mechanistic insight to metabolic contribution to effector T cell function and suggest that T cell function may be finely tuned through modulation of glycolytic activity.